Jon S Odorico, MD


  • Section of Kidney and Pancreas Surgery
  • Division of Transplantation
(608) 263-0388

Clinical Science Center
600 Highland Avenue
Madison WI 53792


  • MD, New York University, School of Medicine, New York, NY, 1987
  • Residency, General Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, 1987-1994
  • Postdoctoral Research Fellow, Harrison Department of Surgical Research, Hospital of the University of Pennsylvania, Philadelphia, PA, 1990-1992
  • Fellow, Transplant Surgery, University of Wisconsin Hospital and Clinics, Madison, WI, 1994-1996

Clinical Specialties

Dr. Odorico is certified by the American Board of Surgery. He specializes in pancreatic, islet cell, and multi-organ transplants.

Dr. Odorico provides a wide range of services including Kidney Transplant, Pancreas Transplant.

Research Interests

Dr. Odorico’s research focuses on stem cell biology and differentiation, developing novel stem cell-based strategies for treating diabetes, pancreas transplantation, and islet cell transplantation.
Dr. Odorico’s lab

Clinical Trials

Conversion from Immediate Release Tacrolimus to Envarsus XR® in Simultaneous Pancreas-Kidney Recipients: Assessment of functional, safety and quality of life outcomes (CIRTEN SPK)
Study sponsor: University of Wisconsin-Madison
Study funding provided by: Veloxis Pharmaceuticals
Jon S. Odorico, MD, Principal Investigator
10/18/2018 –present

Non Invasive Blood Test to Diagnose Acute Rejection After Pancreas and Kidney Transplantation: Pancreas and Renal Rejection Diagnosis Using Circulating Donor-Derived Cell-free DNA in Peripheral Blood (PANCDx)
Study funding provided by: CareDx
Jon S. Odorico, MD, Sub-Investigator
Subcontract Agreement Amendment under negotiation, we expect to start enrollment in the first quarter of 2020

Recent Publications

  • Expanding access to pancreas transplantation for type 2 diabetes mellitus.
    Papageorge CM, Bolognese AC, Odorico JS
    Curr Opin Organ Transplant 2021 Aug 01; 26(4): 390-396
    [PubMed ID: 34148982]

  • Valganciclovir prophylaxis extension from 3 to 6 months in high-risk pancreas-transplant recipients does not impact incidence of cytomegalovirus infection at 12 months.
    Jorgenson MR, Marka N, Leverson GE, Smith JA, Odorico JS
    Clin Transplant 2021 Jun 02; e14379
    [PubMed ID: 34075624]

  • Geographic Distribution of Cytomegalovirus Serology in Kidney and Pancreas Transplant Recipients in the United States.
    Jorgenson MR, Parajuli S, Marka N, Leverson GE, Smith JA, Mandelbrot DA, Odorico JS
    Transplant Direct 2021 Jun; 7(6): e704
    [PubMed ID: 34056079]

  • Pancreas transplant versus islet transplant versus insulin pump therapy: in which patients and when?
    Tamburrini R, Odorico JS
    Curr Opin Organ Transplant 2021 Apr 01; 26(2): 176-183
    [PubMed ID: 33650999]

  • Complex Ureteral Reconstruction in Kidney Transplantation.
    Al-Qaoud TM, Al-Adra DP, Mezrich JD, Fernandez LA, Kaufman DB, Odorico JS, Sollinger HW
    Exp Clin Transplant 2021 May; 19(5): 425-433
    [PubMed ID: 33797353]

All Publications on PubMed